Intellia Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $14,245 | $16,627 | $12,874 | $9,111 |
Gross Profit | 14,245 | 16,627 | 7,700 | 9,111 |
EBITDA | -107,522 | -118,309 | -133,881 | -142,162 |
EBIT | -109,996 | -120,807 | -136,447 | -144,770 |
Net Income | -101,255 | -114,329 | -128,898 | -135,712 |
Net Change In Cash | 14,245 | 16,627 | 12,874 | 9,111 |
Free Cash Flow | -99,861 | -149,665 | -86,176 | -86,116 |
Cash | 156,172 | 126,880 | 189,182 | 120,495 |
Basic Shares | 103,732 | 103,500 | 101,855 | 101,002 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $57,877 | $36,275 | $52,121 | $33,053 |
Gross Profit | 47,592 | 27,299 | 44,549 | 33,053 |
EBITDA | -523,978 | -506,315 | -450,592 | -260,959 |
EBIT | -534,263 | -515,291 | -458,164 | -267,850 |
Net Income | -519,021 | -481,192 | -474,186 | -259,718 |
Net Change In Cash | 57,877 | 36,275 | 52,121 | 33,053 |
Cost of Revenue | 409,977 | -39,120 | ||
Free Cash Flow | -354,658 | -408,071 | -391,677 | -237,786 |
Cash | 189,182 | 226,748 | 523,506 | 123,406 |
Basic Shares | 98,849 | 88,770 | 76,972 | 70,894 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.98 |
2025-03-31 | -$1.10 |
2024-12-31 | -$1.27 |
